Sapient

After another record year ahead of expectations, Publicis unveils AI strategy to lead group into its second century

Retrieved on: 
Thursday, January 25, 2024
Sapient, Heart, Geography, CSO, Intelligence, Consultant, AI, ChatGPT, Software, Intelligent system, Euronext Paris, Acquisition, Publicis, Publicis Sapient, CAC, Growth

In the last 6 years, Publicis has truly become a partner in its clients’ transformation.

Key Points: 
  • In the last 6 years, Publicis has truly become a partner in its clients’ transformation.
  • That platform organization has allowed Publicis to outperform the market on both financial and extra-financial KPIs.
  • Concretely, Publicis is infusing a layer of AI across its platform organization to connect its enterprise knowledge under one entity: CoreAI.
  • Publicis plans to invest three hundred million euros over the next three years as it becomes a true Intelligent System.

Razorfish Promotes Sisi Zhang to Chief Data and Analytics Officer, Welcomes Back Matt Lefever as Chief Operating Officer

Retrieved on: 
Wednesday, January 17, 2024
Other Professional Services, Other Technology, Internet, Electronic Commerce, Data Management, Professional Services, Technology, Digital Marketing, Other Communications, Data Analytics, Public Relations, Investor Relations, Marketing, Advertising, Content Marketing, Communications, Metaverse, Media, Web3, Multimedia, Sapient, Publicis, Investment, Automation, Literature, AI, Growth, Management

Razorfish , a pioneer in digital innovation, today announced the elevation of Sisi Zhang to Chief Data and Analytics Officer, and the hiring of Matt Lefever as Chief Operating Officer.

Key Points: 
  • Razorfish , a pioneer in digital innovation, today announced the elevation of Sisi Zhang to Chief Data and Analytics Officer, and the hiring of Matt Lefever as Chief Operating Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240117571687/en/
    Sisi Zhang, Chief Data and Analytics Officer at Razorfish and Matt Lefever, Chief Operating Officer at Razorfish (Graphic: Business Wire)
    Over the last 12 years, Zhang has played a pivotal role in expanding Razorfish’s data and analytics capabilities, overseeing a team of more than 150 data professionals.
  • Throughout 2023, Zhang spearheaded Razorfish’s increased investments in data automation and engineering skills to keep a competitive edge against rising industry needs.
  • “Sisi exemplifies what it means to be a leader and an innovator,” said Dani Mariano, President of Razorfish.

Pulse Health Names Erwin Tumangday as Strategic Advisor

Retrieved on: 
Wednesday, January 24, 2024
Cloud, Sapient, Organic, Health care, Knowledge, Partnership, Software as a service, American Market, Software, Marketing, Automation, Pleasure, Growth, Medical imaging

NEW YORK, Jan. 24, 2024 /PRNewswire-PRWeb/ -- Today, Pulse Health is pleased to announce the appointment of Erwin Tumangday as Strategic Advisor to the Company. In this new role, Erwin will contribute important and unique insights and share his expertise to help shape the evolution of the firm's products, platforms, and services. His wealth of knowledge will be pivotal in enhancing Pulse Health's engagement strategies with leading healthcare and advertising marketing agencies in the future.

Key Points: 
  • Pulse Health propels forward in its transformative growth phase, injecting fresh momentum with the addition of industry leader Erwin Tumangday to its dynamic strategy team.
  • NEW YORK, Jan. 24, 2024 /PRNewswire-PRWeb/ -- Today, Pulse Health is pleased to announce the appointment of Erwin Tumangday as Strategic Advisor to the Company.
  • - Ryan Alovis, Chief Executive Officer of Pulse Health
    "I'm thrilled to welcome Erwin to Pulse Health's team and am confident that he will help accelerate our firm's growth and leadership in the healthcare industry ecosystem," said Ryan Alovis, CEO of Pulse Health.
  • Erwin is a seasoned healthcare agency growth and partnerships executive with over 25 years of strategic advisory experience.

Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD Study

Retrieved on: 
Tuesday, December 19, 2023
Alternative Medicine, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Veteran, CSR, Food, Trial of the century, FDA, Neuroscience, Therapy, Sapient, Pharmacokinetics, Volunteering, Part, Patient, Safety, Pharmaceutical industry

Sapient Therapeutics Ltd (“Sapient Therapeutics”), a pioneering biopharmaceutical company specialising in neuroscience drug discovery and early clinical development, is pleased to announce the successful completion of Part B of its Phase 1 comparative trial evaluating the safety and pharmacokinetics of its innovative solid dose prescription cannabidiol (CBD), SAP021.

Key Points: 
  • Sapient Therapeutics Ltd (“Sapient Therapeutics”), a pioneering biopharmaceutical company specialising in neuroscience drug discovery and early clinical development, is pleased to announce the successful completion of Part B of its Phase 1 comparative trial evaluating the safety and pharmacokinetics of its innovative solid dose prescription cannabidiol (CBD), SAP021.
  • The positive results of this two-part Phase 1 trial demonstrate the tolerability and bioavailability of Sapient Therapeutics’ lead asset, SAP021, in comparison to Epidiolex®.
  • For and on behalf of Sapient Therapeutics Ltd:
    Sapient Therapeutics is a UK based biopharmaceutical company focused on neuroscience drug discovery and early clinical development.
  • Our lead asset (SAP021) has successfully completed its first Phase 1 study with the Clinical Study Report (CSR) expected in H1 2024.

micromobility.com Appoints Velco Farina as New Board Member

Retrieved on: 
Friday, December 1, 2023
Other Transport, Public Transport, Technology, Transport, Other Technology, Public Policy, Government, Transportation, State, Local, Travel, Tata Communications, Kunai, Multimedia, Sapient, American Express, Bain & Company, Financial services, MBA, Amazon Web Services, Industrial engineering, McKinsey & Company, Fortune 500, Management

micromobility.com Inc. (Nasdaq: MCOM), a leading innovator in the field of sustainable urban transportation, is pleased to announce the appointment of Velco Farina as its newest independent board member of the audit committee of the board of directors of the company.

Key Points: 
  • micromobility.com Inc. (Nasdaq: MCOM), a leading innovator in the field of sustainable urban transportation, is pleased to announce the appointment of Velco Farina as its newest independent board member of the audit committee of the board of directors of the company.
  • With a distinguished career spanning multiple continents and industries, Mr. Farina brings a wealth of experience and expertise to the micromobility.com team.
  • Originally trained as an Industrial Engineer, Velco Farina holds an MBA from SDA Bocconi and UCLA Anderson.
  • His expertise is not limited to executive roles; he also serves on the Board of Torch Systems and the Strategic Board of DIP Capital.

Sapient Therapeutics Announce Positive Results From Phase 1 Part A Trial for Its Solid Dose Prescription CBD

Retrieved on: 
Tuesday, November 21, 2023
Biotechnology, Alternative Medicine, Health, Pharmaceutical, Clinical Trials, Food and Drug Administration, Pharmacokinetics, DSM-IV codes, Safety, Patient, Veteran, Food, Therapy, Sapient, Part, FDA, Pharmaceutical industry, CBD

Sapient Therapeutics Ltd (“Sapient Therapeutics”), a pioneering biopharmaceutical company specialising in neuroscience drug discovery and early clinical development, is pleased to announce the successful completion of its Phase 1 Part A comparative trial evaluating the safety and pharmacokinetics of its innovative solid dose prescription cannabidiol (CBD), SAP021.

Key Points: 
  • Sapient Therapeutics Ltd (“Sapient Therapeutics”), a pioneering biopharmaceutical company specialising in neuroscience drug discovery and early clinical development, is pleased to announce the successful completion of its Phase 1 Part A comparative trial evaluating the safety and pharmacokinetics of its innovative solid dose prescription cannabidiol (CBD), SAP021.
  • The positive results of this Phase 1 Part A trial demonstrate the tolerability and bioavailability of Sapient Therapeutics lead asset, SAP021, in comparison to Epidiolex®.
  • As a result, the Company has progressed this solid dose CBD candidate into Part B of the trial with full results expected in H1 2024.
  • Giles Moss, Chief Executive Officer of Sapient Therapeutics commented: “A solid dose formulation of CBD could provide additional clinical benefit to patients experiencing and suffering from serious neurological diseases.

National Advertising Agency Onboards Doug Jones as Chief Financial Officer and Chief Operating Officer

Retrieved on: 
Monday, September 11, 2023
PLUS Markets Group, Advertising, Razorfish, Bachelor of Science, Marketing, Illinois State University, Golf, Strategic planning, Organization, Publicis, Acquity Group, ANA, Pinnacle, Association of National Advertisers, Growth, Sapient, Financial management, Family, Management, Science

SCHAUMBURG, Ill., Sept. 11, 2023 /PRNewswire/ -- Full-service advertising and marketing agency Pinnacle Advertising & Marketing Group has appointed Doug Jones to the dual role of Chief Financial Officer and Chief Operating Officer. Coming months after the recent appointment of a new Chief Media Officer, this new marketing agency leadership team have joined Pinnacle during an exciting year next level growth for the agency.

Key Points: 
  • SCHAUMBURG, Ill., Sept. 11, 2023 /PRNewswire/ -- Full-service advertising and marketing agency Pinnacle Advertising & Marketing Group has appointed Doug Jones to the dual role of Chief Financial Officer and Chief Operating Officer.
  • Coming months after the recent appointment of a new Chief Media Officer, this new marketing agency leadership team have joined Pinnacle during an exciting year next level growth for the agency.
  • Jones, an experienced advertising, and marketing finance and operations executive, with more than 25 years of strategic leadership.
  • Outside of work, he splits time between family, volunteering for local organizations, and an occasional round of golf.

Sapient’s High Complexity CLIA Laboratory Receives Accreditation from the College of American Pathologists (CAP)

Retrieved on: 
Wednesday, August 2, 2023
Research, Clinical Trials, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Accreditation, CLIA, College, MD, Culture, Metabolomics, Doctor of Philosophy, CAP, Nursing, Sapient

Sapient , a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis, announced that its high complexity CLIA laboratory has been awarded accreditation from the College of American Pathologists ( CAP ).

Key Points: 
  • Sapient , a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis, announced that its high complexity CLIA laboratory has been awarded accreditation from the College of American Pathologists ( CAP ).
  • To achieve accreditation, Sapient passed a rigorous evaluation process that involved an in-depth inspection of its clinical laboratory facilities, equipment, processes, quality control measures, and personnel qualifications.
  • “As a CLIA-certified lab performing advanced biomarker assays that are deemed ‘high complexity’ , we must adhere to the most stringent CLIA regulations.
  • Accreditation by CAP confirms that we uphold or exceed these high standards with exceptional testing proficiency, accuracy, and reliability,” said Nilesh Dharajiya, MD, CLIA Lab Director at Sapient.

Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer

Retrieved on: 
Thursday, July 13, 2023
SPAC, CGT, Corporate finance, Biotechnology, Elon University, Accounting, Growth, Sapient, Treasurer, Market for corporate control, Management, Finance

Mr. Maltz, previously served as the Chief Financial Officer of Gelesis, Inc., a commercial stage biotherapeutics company, since May 2021 and as its Treasurer since May 2015.

Key Points: 
  • Mr. Maltz, previously served as the Chief Financial Officer of Gelesis, Inc., a commercial stage biotherapeutics company, since May 2021 and as its Treasurer since May 2015.
  • As Chief Financial Officer, Mr. Maltz led numerous fundraising and operational initiatives, including the efforts to take Gelesis, Inc. public through a SPAC merger in January 2022, whereupon he became the Chief Financial Officer and Treasurer of Gelesis Holdings, Inc.
  • Prior to his appointment as the Chief Financial Officer, Mr. Maltz was Gelesis, Inc.’s Vice President of Finance and previously served as its Corporate Controller.
  • Vered Caplan, CEO of Orgenesis, stated, "I am honored to announce the appointment of Elliot Maltz as Chief Financial Officer, which is especially timely as we enter the next phase of our growth.

Apexon Extends Leadership Team with Three Key Appointments

Retrieved on: 
Monday, June 19, 2023
Software, Data Analytics, Data Management, Professional Services, Technology, Apps, Applications, Other Technology, Business, Wipro, HCLTech, Santander Consumer Bank (Deutschland), Srinivas, Kabra, Queensland, Cognizant, Goldman Sachs, Intelligence, Tech Mahindra, Running, Growth, Tesco, Sapient, Citibank, Virtusa, Management

He previously led the global talent supply chain function at Wipro Technologies, following several impactful roles at Cognizant Technology Solutions.

Key Points: 
  • He previously led the global talent supply chain function at Wipro Technologies, following several impactful roles at Cognizant Technology Solutions.
  • His expertise in operations management and artificial intelligence makes him an important addition to the Apexon team.
  • “As our clients aspire to achieve ambitious digital transformation goals, they consistently choose Apexon as their preferred technology partner,” said Sriniketh Chakravarthi, Chief Executive Officer of Apexon.
  • I eagerly anticipate collaborating with them, harnessing their combined experience, leadership skills, and unwavering commitment to excellence as we unlock exciting new growth opportunities.”